Focus
Our research group focuses on the development and clinical translation of radiopharmaceutical therapeutics for applications in oncology.
We are currently evaluating two astatinated alpha-emitting radiotherapeutics including [211At]MABG (norepinephrine substrate) and [211At]MM4 (PARP inhibitor) for the treatment of neuroblastoma. The development of [211At]MABG is highly collaborative between the Pryma and Maris lab (CHOP) with high potential for clinical translation in the near future. Dan Pryma’s clinical work led to the [131I]MIBG FDA approval for the treatment of pheochromocytoma. The Makvandi lab studies the relative biological effectiveness of alpha-particles and auger electrons using radiopharmaceuticals which target the DNA within the nucleus in engineered cell systems.
Faculty And Staff
Daniel Pryma, MD
- Chief, Division of Nuclear Medicine Imaging and Therapy
- Gerd Muehllehner Professor of Radiology
View Full Profile
Adam Mansfield
Researcher
Recent Publications
1. Pryma, et al. Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019 May;60(5):623-630. doi: 10.2967/jnumed.118.217463. Epub 2018 Oct 5.
2. Reilly SW, Makvandi M, Xu K, Mach RH. Rapid Cu-Catalyzed [211At]Astatination and [125I]Iodination of Boronic Esters at Room Temperature. Org Lett. 2018 Apr 6;20(7):1752-1755. doi: 10.1021/acs.orglett.8b00232. Epub 2018 Mar 21.
3. McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku A, Selvakumar D, Carlin SD, Lewis JS, Viola-Villegas NT. Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep. 2018 Jun 13;8(1):9043. doi: 10.1038/s41598-018-27454-6.
Contact Us
Daniel Pryma, MD
215-349-5272
daniel.pryma@uphs.upenn.edu
Sandra Carney
sandra.carney@uphs.upenn.edu